scholarly journals A need for rigorous review of literature for development of new drugs in Ayurveda

The Healer ◽  
2021 ◽  
Vol 2 (02) ◽  
pp. I-III
Author(s):  
Prof Rabinarayan Acharya
Keyword(s):  
Health Care ◽  
Health Care System ◽  
Life Sciences ◽  
New Drugs ◽  
Review Of Literature ◽  
Treatment Protocols ◽  
Logical Foundation ◽  
Time Period ◽  
Prevention And Cure ◽  
Care System

Ayurveda, one of the oldest life sciences, had been evolved in India, and stands still on a rational and logical foundation with own fundamental principles which guides the society towards prevention of diseases, to maintain the health through prevention and cure of ailments. The genesis and development of Ayurveda stream, as a health care system, is well supported by a robust literature being fortified with numerous experience-based treatment protocols. The available literature of Ayurveda, based on time period, can grossly be divided into three categories i.e., Veda, Samhita and Samgraha period.................       

scholarly journals Motivations and Experiences of Canadians Seeking Treatment for Lyme Disease Outside of the Conventional Canadian Health-Care System

2017 ◽  
Vol 5 (2) ◽  
pp. 120-126 ◽  
Author(s):  
Corinne R Boudreau ◽  
Vett K Lloyd ◽  
Odette N Gould
Keyword(s):  
Health Care ◽  
Lyme Disease ◽  
Health Care System ◽  
Diagnostic Procedures ◽  
Advocacy Groups ◽  
Treatment Protocols ◽  
Canadian Health Care System ◽  
Canadian Health ◽  
Canadian Health Care ◽  
Care System

Objective: We aimed to describe the experiences of Canadians who seek diagnosis and treatment for Lyme disease outside of the conventional Canadian health-care system. Methods: Forty-five individuals who had sought treatment for Lyme disease outside of the conventional Canadian health-care system were recruited from Lyme support and advocacy groups across Canada to answer open-ended questions about their experiences. Results: Respondents sought treatment outside of the conventional medical system due to extensive diagnostic procedures and treatments that did not resolve symptoms. Escalating health concerns, lack of effective treatment, and stigma produced a sense of abandonment and desperation. Respondents accessed alternative forms of care based on the recommendations of peers, yet considerable financial and emotional stress was experienced. Conclusions: Many individuals with Lyme or Lyme-like diseases are deeply dissatisfied with the care received within the conventional Canadian health-care system and therefore felt both pushed and pulled to seek treatments either from international physicians using different treatment protocols or from alternative medicine providers in Canada.

scholarly journals Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2126-2126
Author(s):  
Hishaam Bhimji ◽  
Dean Eurich ◽  
Kerry Mansell ◽  
Holly Mansell
Keyword(s):  
Health Care ◽  
Health Care System ◽  
Cost Savings ◽  
Cost Effective ◽  
Potential Cost ◽  
Significant Cost ◽  
Term Care ◽  
Time Period ◽  
The Cost ◽  
Care System

Background: Filgrastim was first introduced to the Canadian marketplace as Neupogen® in 1992 to treat neutropenia caused by chemotherapy regimens. In 2009, the first biosimilar drug was approved for use in Canada, and in March 2016, a biosimilar for filgrastim (Grastofil®) became available. Biosimilars represent safe, effective, and cost effective alternatives to originator biologic medications. However, although biosimilar medications present opportunities for significant cost savings to the health care system, overall uptake and use of biosimilar medications in North America has been low. The aim of this study was to describe the overall use of the filgrastim products Grastofil® and Neupogen® in Canada. Methods: A retrospective analysis of Canadian drug purchases between July 2016 and June 2018 was performed for the drug filgrastim (Neupogen®, Grastofil®). The data used to estimate drug purchases were obtained from IQVIA™, a multi-national healthcare analytics company. Samples from the IQVIA™ Canadian Drugstore and Hospital Purchases (CDH) audit covered greater than 88% of the hospital market and one-third of the retail market. Samples were stratified by region, market size, and type of outlet (e.g. cancer centers, long-term care). For each drug, the total purchase dollar amounts were provided by province on a month by month basis. Potential cost-savings were calculated as a product between the units of each product purchased and the cost difference between Neupogen® and the biosimilar Grastofil® on a quarterly basis for each province. Results: Between July 1st, 2016 and June 30th, 2018, Grastofil® accounted for 27.0% (382,254/1,415,762 units) of filgrastim purchases. During this time period, $62,061,576 was spent on Grastofil® purchases and $204,152,590 was spent on Neupogen® purchases. Through use of the biosimilar Grastofil®, $13,443,873 (37.0%) in savings were realized. Had there been 100% use of the biosimilar Grastofil®, it would have resulted in $36,348,476 in cost savings. In the first quarter (July to September 2016) Grastofil® accounted for 1.5% of filgrastim purchases, whereas in the April to June 2018 quarter it increased to 43.6% of filgrastim purchases. The overall percentage of filgrastim units purchased by Canadian province varied substantially. The market share captured by Grastofil® ranged from a low of 0.08% ($4007/$5,189,623) in the province of Nova Scotia, to a high of 81.62% ($932,864/$1,142,905) in the province of Saskatchewan. Canada's largest province, Ontario, saw Grastofil® account for 44.7% ($9,047,489/$20,229,421) of purchases during this time period. Discussion: Although the biosimilar Grastofil® only accounted for 27% of filgrastim purchases between 2016 and 2018, there was substantial growth over this time period. By the end of June 2018, Grastofil® accounted for approximately 44% of filgrastim purchases, which is substantially higher than other biosimilar medications currently available in Canada. There are also stark differences between each province, whereas some had little to no use of the biosimilar, whereby in other provinces the purchases of Grastofil® outnumbered the purchases of Neupogen®. Had there been exclusive use of the biosimilar, an additional $23 million dollars in savings could have been realized. Conclusions: The use of biosimilars represents an opportunity for cost savings to be realized in an over-extended health care system. Although there appears to be acceptance for the use of Grastofil® as the overall purchases trended up from 2016 to 2018, there are still significant cost savings that could be realized by greater use of biosimilar drugs. Disclosures Mansell: Apobiologix: Research Funding.

Teletinnitus Program at the VA Gulf Coast Veterans Health Care System

2014 ◽  
Vol 4 (1) ◽  
pp. 23-29
Author(s):  
Constance Hilory Tomberlin
Keyword(s):  
Health Care ◽  
Patient Satisfaction ◽  
Patient Care ◽  
Health Care System ◽  
Gulf Coast ◽  
New Technology ◽  
Cost Effective ◽  
Veterans Health ◽  
Potential Benefits ◽  
Care System

There are a multitude of reasons that a teletinnitus program can be beneficial, not only to the patients, but also within the hospital and audiology department. The ability to use technology for the purpose of tinnitus management allows for improved appointment access for all patients, especially those who live at a distance, has been shown to be more cost effective when the patients travel is otherwise monetarily compensated, and allows for multiple patient's to be seen in the same time slots, allowing for greater access to the clinic for the patients wishing to be seen in-house. There is also the patient's excitement in being part of a new technology-based program. The Gulf Coast Veterans Health Care System (GCVHCS) saw the potential benefits of incorporating a teletinnitus program and began implementation in 2013. There were a few hurdles to work through during the beginning organizational process and the initial execution of the program. Since the establishment of the Teletinnitus program, the GCVHCS has seen an enhancement in patient care, reduction in travel compensation, improvement in clinic utilization, clinic availability, the genuine excitement of the use of a new healthcare media amongst staff and patients, and overall patient satisfaction.

What is the best way to reform the U.S. health care system?

2007 ◽  
Vol 38 (1) ◽  
pp. 18
Author(s):  
KEVIN GRUMBACH ◽  
ROBERT MOFFIT
Keyword(s):  
Health Care ◽  
Health Care System ◽  
The U.S ◽  
Care System

U.S. Health Care System Ranks Last in Six-Country Comparison

2010 ◽  
Vol 41 (8) ◽  
pp. 38
Author(s):  
NASEEM S. MILLER
Keyword(s):  
Health Care ◽  
Health Care System ◽  
Country Comparison ◽  
Care System

What is the best way to reform the U.S. health care system?

2007 ◽  
Vol 40 (1) ◽  
pp. 6
Author(s):  
KEVIN GRUMBACH ◽  
ROBERT MOFFIT
Keyword(s):  
Health Care ◽  
Health Care System ◽  
The U.S ◽  
Care System

Commitment and cost control in the health care system.

1982 ◽  
Vol 37 (12) ◽  
pp. 1359-1361 ◽  
Author(s):  
Carolyne K. Davis
Keyword(s):  
Health Care ◽  
Health Care System ◽  
Cost Control ◽  
Care System
Sign in / Sign up

Export Citation Format

Share Document